Core Viewpoint - Fosun Pharma showcases its innovative products and global collaborations at the 8th China International Import Expo, highlighting its deep commitment to the global healthcare sector and continuous breakthroughs [1][3]. Group 1: Product Innovation and Localization - Fosun Pharma has successfully localized several innovative products, including the Da Vinci surgical robot and CAR-T cell therapy product Yikaida, benefiting numerous Chinese patients and enhancing industry standards [3]. - The Yikaida product has treated over 1,000 lymphoma patients since its debut at the first Import Expo in 2018, marking significant advancements in commercial insurance and clinical efficacy [3]. - The Da Vinci surgical robot has been installed over 460 times in mainland China and Hong Kong, serving more than 810,000 patients, with new systems showcased this year expanding its capabilities in minimally invasive surgery [3]. Group 2: Infrastructure and Investment - The launch of the Intuitive Medical headquarters in Shanghai, with an investment of approximately 700 million yuan, marks a significant shift for Fosun Pharma from exhibitor to investor, strengthening its local industrial foundation [4]. - The Magnetic Resonance Guided Focused Ultrasound system has been introduced to over ten key medical institutions in China, treating nearly 1,000 patients, with the new V2 model receiving CE and FDA certifications [4]. Group 3: Strategic Collaborations and Global Operations - Fosun Pharma's Marie® upright particle therapy system, recently FDA approved, represents a new approach to tumor treatment, significantly reducing construction and operational costs while accommodating various advanced therapies [6]. - A strategic partnership with Leo Cancer Care aims to accelerate the introduction of this technology in China, enhancing treatment accessibility for cancer patients [8]. - The company employs a dual strategy of "independent research and development + cooperative introduction," focusing on cutting-edge fields such as antibody therapy, ADC, and gene editing [8]. Group 4: International Expansion and Market Presence - Fosun Pharma's internationalization has progressed beyond trade, entering a new phase of "global operations," with over 1,000 overseas commercialization teams established in markets like the US, Europe, and Southeast Asia [8]. - In the first half of 2025, overseas revenue reached 5.478 billion yuan, accounting for 28.07% of total revenue, indicating strong international market penetration [8]. - The company's self-developed PD-1 inhibitor has been approved in nearly 40 countries, establishing a benchmark for "Chinese innovation going global" [8]. Group 5: Industry Impact and Future Outlook - Fosun Pharma's comprehensive global capabilities are reshaping the international competitiveness of Chinese pharmaceutical companies, serving as a model for industry innovation and integration in an era of global adjustment [9].

Core Insights - The China International Import Expo (CIIE) serves as a significant platform for listed companies to showcase their products and technologies, reflecting the vibrancy and attractiveness of the Chinese market [1][8] - Central enterprises play a crucial role in procurement, facilitating deeper connections within global supply chains and showcasing new products and technologies from multinational companies [2][3] Group 1: Central Enterprises and Procurement - A total of 14 central enterprises participated in the "Central Enterprise Procurement Corridor," leading to numerous procurement agreements that enhance global supply chain connections [2] - China National Offshore Oil Corporation (CNOOC) achieved a record signing amount of over $13 billion at the expo, covering oil, gas, and advanced technology services [2] - China Eastern Airlines signed 19 procurement agreements with suppliers from 9 countries, totaling $1.211 billion, focusing on high-tech products in the aviation sector [3] Group 2: Product Showcases and Innovations - Fosun Pharma showcased innovative products in cancer treatment and other medical fields, including the revolutionary Marie® particle therapy system, which reduces costs and allows for rapid deployment in existing medical spaces [4][5] - Rebeca, a leading company in the wig industry, presented a fashion show to highlight its products, aiming to elevate "Xuchang manufacturing" to an international level [6] Group 3: Operational Support and Safety - The smooth operation of the expo relied on comprehensive support services, with companies like Shanghai Construction Group providing maintenance for over 24,000 facilities and equipment [7] - The "Smart City Cloud Aid" emergency system was implemented to ensure safety, featuring real-time monitoring and rapid response capabilities [7] Group 4: Overall Impact and Collaboration - The active participation of listed companies at the expo illustrates a dynamic scene of openness, innovation, and collaboration, contributing to the integration of the Chinese economy with the global economy [8]

Group 1: Event Overview - The 8th China International Import Expo (CIIE) will be held in Shanghai from November 5 to 10, attracting participation from 155 countries, regions, and international organizations, with over 4,108 foreign enterprises exhibiting [1] - The overall exhibition area exceeds 430,000 square meters, setting a new record for the event, showcasing numerous representative new products, technologies, and services [1] Group 2: Notable Exhibits - Becton Dickinson (BD) showcased several global and China-first products, including the Ferghana needle-free intravenous catheter designed to reduce needle-stick injury risks and enhance healthcare worker safety [1] - The new 3DMax hernia repair patch features a unique 3D structure and anatomical positioning lines, improving surgical efficiency and reducing postoperative pain [1] - Fosun Pharma presented the Marie® upright particle therapy system, a revolutionary breakthrough in tumor treatment that offers a cost-effective and space-saving alternative to traditional systems [3] Group 3: Industry Impact - The CIIE serves as a platform for companies to transform exhibits into commercial products, with many exhibitors becoming investors [6] - Tutti Pharma, which successfully entered the Chinese market after the previous CIIE, reported sales exceeding expectations in the first quarter and plans to invest in a local manufacturing facility [6] - The company aims to establish a comprehensive clinical trial and product development system in China, with aspirations to expand into Southeast Asian markets [6] Group 4: Technological Innovations - Tesla's Cybercab, an autonomous electric vehicle, made its Asia-Pacific debut, featuring a streamlined design without a steering wheel or pedals [5] - The Cybercab utilizes Tesla Vision and end-to-end neural network technology for autonomous driving, eliminating the need for expensive lidar hardware, and is set for mass production in Q2 2026 [5]

Core Viewpoint - Fosun Pharma will showcase its innovative pharmaceutical products and high-end medical devices at the 8th China International Import Expo (CIIE), emphasizing its role as a global healthcare industry leader rooted in China [1][2]. Group 1: Company Achievements - Fosun Pharma has successfully transformed from an exhibitor to an investor, leveraging the CIIE to accelerate the localization of advanced technologies and innovative medical products in China [1]. - The company has introduced at least six innovative products, referred to as "CIIE babies," which have been successfully launched or approved in China, including the Da Vinci surgical robot and the CAR-T cell therapy product Yikaida® [2][3]. Group 2: Product Innovations - The Marie® vertical particle therapy system, a revolutionary breakthrough in tumor radiotherapy, has been highlighted for its compact design, reducing the required space from 120 square meters to 30 square meters, thus lowering construction and operational costs [2]. - Yikaida®, as China's first approved CAR-T product, has benefited over 1,000 lymphoma patients since its approval in 2021, showcasing the positive impact of the CIIE on global resource collaboration [3]. Group 3: Future Directions - Fosun Pharma aims to focus on industry upgrades and embrace innovative products in future CIIE participations, seeking to gather more global resources as a multinational enterprise [3].